

Aberystwyth University

Perspective on Schistosomiasis Drug Discovery

Caldwell, Nicola; Afshar, Rana; Baragaña, Beatriz; Bustinduy, Amaya L; Caffrey, Conor R; Collins, James J; Fusco, Daniela; Garba, Amadou; Gardner, Mark; Gomes, Mireille; Hoffmann, Karl F; Hsieh, Michael; Lo, Nathan C; McNamara, Case W; Nono, Justin Komguez; Padalino, Gilda; Read, Kevin D; Roestenberg, Meta; Spangenberg, Thomas; Specht, Sabine

Published in:
ACS Infectious Diseases

DOI:
[10.1021/acscinfecdis.3c00081](https://doi.org/10.1021/acscinfecdis.3c00081)

Publication date:
2023

Citation for published version (APA):
Caldwell, N., Afshar, R., Baragaña, B., Bustinduy, A. L., Caffrey, C. R., Collins, J. J., Fusco, D., Garba, A., Gardner, M., Gomes, M., Hoffmann, K. F., Hsieh, M., Lo, N. C., McNamara, C. W., Nono, J. K., Padalino, G., Read, K. D., Roestenberg, M., Spangenberg, T., ... Gilbert, I. H. (2023). Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022. *ACS Infectious Diseases*, 9(5), 1046-1055. <https://doi.org/10.1021/acscinfecdis.3c00081>

Document License CC BY

General rights

Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

tel: +44 1970 62 2400
email: is@aber.ac.uk

Schistosomiasis Drug Discovery Workshop

Wellcome Collection, London

22nd – 23rd September 2022

Meeting Program

Thursday 22nd September

09.20 – 10.00	Arrival		
09.20	Arrival and welcome		
09.40	Ian Gilbert	Opening remarks	
10.00 – 11.20	Session 1	Current progress with new treatments – key compounds and human trials	<i>Chair: Nicola Caldwell</i>
10.00	Rana Afshar	Arpraziquantel development program update	
10.20	Thomas Spangenberg	Update on clinical progress of Salvensis compound	
10.40	Nathan Lo	Modelling of novel drugs against Schistosoma	
11.00	Panel discussion with all session 1 speakers		
11.20	Break		
11.40 – 13.00	Session 2	Urogenital schistosomiasis – key requirements for new treatments	<i>Chair: Amaya Bustinduy</i>
11.40	Mireille Gomes	FGS	
12.00	Daniela Fusco	FGS and key requirements for new treatments	
12.20	Michael Hsieh	MGS and in vivo models for FGS	
12.40	Panel discussion with all session 2 speakers		
13.00 – 14.00	Lunch		
14.00 – 14.50	Session 3	Target product profiles for FGS and MGS	<i>Chair: Sabine Specht + Daniela Fusco</i>
14.00	Discussion session		
14.50 – 16.50	Session 4	Drug discovery pathway and critical assays	<i>Chair: Kevin Read</i>
14.50	Karl Hoffmann	Aberystwyth University screening platform	
15.10	Conor Caffrey	UC San Diego screening platform	
15.30	Break		
15.50	Jim Collins	RNAi screening	
16.10	Meta Roestenberg	Human challenge model	
16.30	Panel discussion with all session 4 speakers		
16.50 – 17.00	Day 1 finish		

Schistosomiasis Drug Discovery Workshop

Wellcome Collection, London

22nd – 23rd September 2022

Meeting Program

Friday 23rd September

09.00 – 10.00	Session 5	Defining a target product profile for schistosomiasis	<i>Chair: Beatriz Baragaña</i>
09.00	Justin Nono Komguez	Key requirements for new treatments in endemic areas	
09.20	Amadou Garba Djirmay	WHO perspective on new drugs for schistosomiasis	
09.40	Panel discussion with all session 5 speakers		
10.00 – 10.50	Session 6	Target product profiles for schistosomiasis	<i>Chair: Sabine Specht + Ian Gilbert</i>
10.00	Discussion session		
10.50 – 11.10	Break		
11.10 – 12.50	Session 7	Drug discovery and compound progression criteria	<i>Chair: Karl Hoffmann</i>
11.10	Gilda Padalino	Schistosomiasis drug discovery at Cardiff University	
11.30	Nicola Caldwell	Schistosomiasis drug discovery at Dundee University	
11.50	Case McNamara	Calibr workstream and screening	
12.10	Mark Gardner	Progression criteria in the discovery of the Salvensis series	
12.30	Panel discussion with all session 5 speakers		
12.50 – 13.00	Closing remarks		
12.50	Ian Gilbert	Closing remarks	
13.00 – 14.00	Lunch		